1e
19
1
49
2
2
18
1b
1d
18
35
72
1d
2 29
1d
25
Michael J. Fisher, M.D.
88
72
Professor of Pediatrics (Oncology) at the Children's Hospital of Philadelphia
28
ae
3
61
Attending Physician, Center for Childhood Cancer Research and Division of Oncology, Children's Hospital of Philadelphia
68
Member, Cancer Center, University of Pennsylvania
81
Director, Neurofibromatosis Program, Children’s Hospital of Philadelphia
91
Chief, Neuro-Oncology Section, Division of Oncology, Children’s Hospital of Philadelphia
b0
Hubert J.P. and Anne Faulkner Schoemaker Endowed Chair in Pediatric Neuro-Oncology, Children’s Hospital of Philadelphia
11
Department: Pediatrics
4
1
b
1d
46
Contact information
6b
4
3
3
3
2
29
4
b
1f
6b
Center for Childhood Cancer Research and Division of Oncology
31 The Children’s Hospital of Philadelphia
36 The Hub for Clinical Collaboration - 3rd Floor
3a 3500 Civic Center Blvd.
Philadelphia, PA 19104
26
31 The Children’s Hospital of Philadelphia
36 The Hub for Clinical Collaboration - 3rd Floor
3a 3500 Civic Center Blvd.
Philadelphia, PA 19104
2f
Office: (215)590-2800
30
8d
30
Email:
fisherm@email.chop.edu
12
fisherm@email.chop.edu
13
Education:
21 5 c
47 Eberhard-Karls Universitaet, Tubingen, Germany, 1987.
21 9 B.A. 28 (Psychology, Summa cum Laude) c
28 Amherst College, 1989.
21 9 M.D. c
3b Harvard Medical School (cum Laude), 1994.
c
3
3
3
3
8b
Permanent link21 5 c
47 Eberhard-Karls Universitaet, Tubingen, Germany, 1987.
21 9 B.A. 28 (Psychology, Summa cum Laude) c
28 Amherst College, 1989.
21 9 M.D. c
3b Harvard Medical School (cum Laude), 1994.
c
2 29
21
1e
1d
24
2b
29
27
23
233 Fathi Kazerooni A, Kraya A, Rathi KS, Kim MC, Vossough A, Khalili N, Familiar AM, Gandhi D, Khalili N, Kesherwani V, Haldar D, Anderson H, Jin R, Mahtabfar A, Bagheri S, Guo Y, Li Q, Huang X, Zhu Y, Sickler A, Lueder MR, Phul S, Koptyra M, Storm PB, Ware JB, Song Y, Davatzikos C, Foster JB, Mueller S, Fisher MJ, Resnick AC, Nabavizadeh A: Multiparametric MRI along with machine learning predicts prognosis and treatment response in pediatric low-grade glioma. Nat Commun 16(1): 340, 2025.
1da Nakhate V, Ly I, Muzikansky A, Rapalino O, Allen JC, Blakeley JO, Campian JL, Clapp DW, Dhall G, Jain RK, Karajannis MA, Packer RJ, Tonsgard J, Ullrich NJ, Korf BR, Fisher MJ, Plotkin SR, Neurofibromatosis Clinical Trials Consortium.: Effect of bevacizumab on non-target intracranial meningiomas and non-vestibular schwannomas in NF2-related schwannomatosis: NF104. J Neurooncol 173(3): 751-757, 2025.
1dd Barton B, Wolters PL Walsh KS, Ullrich NJ, Rosser T, Tonsgard J, Viskochil D, Schorry E,. Klesse LJ, Fisher MJ, Gutmann DH, Packer RJ, Korf B, Acosta MT, North KN, and Payne JM, for the NF Clinical Trials Consortium: Psychosocial functioning and determinants of the health-related quality of life in children with neurofibromatosis type 1 and cognitive impairments. J Neuro-Oncology 174(1): 65-76, 2025.
2c2 O’Hare P, Cooney T, de Blank P, Gutmann D, Kieran M, Milde T, Fangusaro J, Fisher MJ, Avula S, Packer R, Fukuoka K, Mankad K, Mueller S, Waanders AJ, Opocher E, Bouffet E, Raabe E, Natacha EW, Azizi A, Robison N, Hernáiz Driever P, Russo M, Schouten N, van Tilburg C, Sehested A, Grill J, Bandopadhayay P, Kilday J-P, Witt O, Ashley DM, Ertl-Wagner BB, Tabori U, Hargrave D: Resistance, rebound and recurrence regrowth patterns in pediatric low-grade glioma: a modified Delphi approach to develop international consensus-based definitions. International Pediatric Low-Grade Glioma Coalition. Neuro-Oncology 26(8): 1357-1366, 2024.
1c1 John L, Singh G, Dombi E, Wolters P, Martin S, Baldwin A, Steinberg S, Bernstein J, Whitcomb P, Pichard D, Dufek A, Gillespie A, Heisey K, Bornhorst M, Fisher M, Weiss B, Kim A, Widemann B, Gross A: Development and pilot validation of a novel disfigurement severity scale for plexiform neurofibromas in children with neurofibromatosis type 1. Clin Trials 21(2): 189-198, 2024.
193 Gross AM, Plotkin S, Watts N, Fisher M, Klesse L, Lessing A, McManus M, Larson AN, Oberlander B, Rios J, Sarnoff H, Simpson B, Ullrich N, Stevenson D, on behalf of the REiNS International Collaboration: Potential Endpoints for Assessment of Bone Health in Persons with Neurofibromatosis Type 1. Clinical Trials 21(1): 29-39, 2024.
ff Hocking MC, Albee MV, Kim M, Berman JI, Fisher MJ, Roberts TPL, Blaskey L: Social Challenges, Autism Spectrum Disorder, and Attention Deficit/Hyperactivity Disorder in Youth with Neurofibromatosis Type I. 45 Applied Neuropsychology Child 12: 1-9, 2024.
18a Estrela T, Truong S, Garcia A, He J, Ying G-S, Devakandan K, Reginald AR, Fisher MJ, Liu GT, Ullrich NJ, Avery RA, Heidary G: The Relationship between Choroidal Abnormalities and Visual Outcomes in Pediatric Patients with NF1-associated Optic Pathway Gliomas: A Longitudinal Study. J Neuro-Ophthalmology 44(1): 5-9, 2024.
1b9 Plotkin SR, Allen J, Dhall G, Campian, JL, Clapp DW, Fisher MJ, Jain RK, Tonsgard J, Ullrich NJ, Thomas C, Edwards LJ, Korf B, Packer R, Karajannis MA, Blakeley JO: Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma. Neuro-Oncol 25(8): 1498-1506, Aug 2023.
2c
7
1d
1f
Selected Publications
4d7 Lamoureux AA*, Fisher MJ*, Lemelle L, Pfaff E, Amir-Yazdani P, Kramm C, De Wilde B, Kazanowska B, Hutter C, Pfister SM, Sturm D, Jones DTW, Orbach D, Pierron G, Raskin S, Drilon A, Diamond EL, Harada G, Zapotocky M, Zamecnik J, Krskova L, Ellezam B, Weil AG, Venne D, Barritault M, Leblond P, Coltin H, Hammad R, Tabori U, Hawkins C, Hansford JR, Meyran D, Erker C, McFadden K, Sato M, Gottardo NG, Dholaria H, Nørøxe DS, Goto H, Ziegler DS, Lin FY, Parsons DW, Lindsay H, Wong TT, Liu YL, Wu KS, Franson AT, Hwang E, Aguilar-Bonilla A, Cheng S, Cacciotti C, Massimino M, Schiavello E, Wood P, Hoffman LM, Cappellano A, Lassaletta A, Van Damme A, Llort A, Gerber NU, Spalato Ceruso M, Bendel AE, Skrypek M, Hamideh D, Mushtaq N, Walter A, Jabado N, Alsahlawi A, Farmer JP, Coleman C, Mueller S, Mazewski C, Aguilera D, Robison NJ, O'Halloran K, Abbou S, Berlanga P, Geoerger B, Øra I, Moertel CL, Razis ED, Vernadou A, Ducray F, Bronnimann C, Seizeur R, Clarke M, Resnick AC, Alves M, Jones C, Doz F, Laetsch TW, Perreault S: Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions. Clin Cancer Res 31(3): 561-572, 2025.233 Fathi Kazerooni A, Kraya A, Rathi KS, Kim MC, Vossough A, Khalili N, Familiar AM, Gandhi D, Khalili N, Kesherwani V, Haldar D, Anderson H, Jin R, Mahtabfar A, Bagheri S, Guo Y, Li Q, Huang X, Zhu Y, Sickler A, Lueder MR, Phul S, Koptyra M, Storm PB, Ware JB, Song Y, Davatzikos C, Foster JB, Mueller S, Fisher MJ, Resnick AC, Nabavizadeh A: Multiparametric MRI along with machine learning predicts prognosis and treatment response in pediatric low-grade glioma. Nat Commun 16(1): 340, 2025.
1da Nakhate V, Ly I, Muzikansky A, Rapalino O, Allen JC, Blakeley JO, Campian JL, Clapp DW, Dhall G, Jain RK, Karajannis MA, Packer RJ, Tonsgard J, Ullrich NJ, Korf BR, Fisher MJ, Plotkin SR, Neurofibromatosis Clinical Trials Consortium.: Effect of bevacizumab on non-target intracranial meningiomas and non-vestibular schwannomas in NF2-related schwannomatosis: NF104. J Neurooncol 173(3): 751-757, 2025.
1dd Barton B, Wolters PL Walsh KS, Ullrich NJ, Rosser T, Tonsgard J, Viskochil D, Schorry E,. Klesse LJ, Fisher MJ, Gutmann DH, Packer RJ, Korf B, Acosta MT, North KN, and Payne JM, for the NF Clinical Trials Consortium: Psychosocial functioning and determinants of the health-related quality of life in children with neurofibromatosis type 1 and cognitive impairments. J Neuro-Oncology 174(1): 65-76, 2025.
2c2 O’Hare P, Cooney T, de Blank P, Gutmann D, Kieran M, Milde T, Fangusaro J, Fisher MJ, Avula S, Packer R, Fukuoka K, Mankad K, Mueller S, Waanders AJ, Opocher E, Bouffet E, Raabe E, Natacha EW, Azizi A, Robison N, Hernáiz Driever P, Russo M, Schouten N, van Tilburg C, Sehested A, Grill J, Bandopadhayay P, Kilday J-P, Witt O, Ashley DM, Ertl-Wagner BB, Tabori U, Hargrave D: Resistance, rebound and recurrence regrowth patterns in pediatric low-grade glioma: a modified Delphi approach to develop international consensus-based definitions. International Pediatric Low-Grade Glioma Coalition. Neuro-Oncology 26(8): 1357-1366, 2024.
1c1 John L, Singh G, Dombi E, Wolters P, Martin S, Baldwin A, Steinberg S, Bernstein J, Whitcomb P, Pichard D, Dufek A, Gillespie A, Heisey K, Bornhorst M, Fisher M, Weiss B, Kim A, Widemann B, Gross A: Development and pilot validation of a novel disfigurement severity scale for plexiform neurofibromas in children with neurofibromatosis type 1. Clin Trials 21(2): 189-198, 2024.
193 Gross AM, Plotkin S, Watts N, Fisher M, Klesse L, Lessing A, McManus M, Larson AN, Oberlander B, Rios J, Sarnoff H, Simpson B, Ullrich N, Stevenson D, on behalf of the REiNS International Collaboration: Potential Endpoints for Assessment of Bone Health in Persons with Neurofibromatosis Type 1. Clinical Trials 21(1): 29-39, 2024.
ff Hocking MC, Albee MV, Kim M, Berman JI, Fisher MJ, Roberts TPL, Blaskey L: Social Challenges, Autism Spectrum Disorder, and Attention Deficit/Hyperactivity Disorder in Youth with Neurofibromatosis Type I. 45 Applied Neuropsychology Child 12: 1-9, 2024.
18a Estrela T, Truong S, Garcia A, He J, Ying G-S, Devakandan K, Reginald AR, Fisher MJ, Liu GT, Ullrich NJ, Avery RA, Heidary G: The Relationship between Choroidal Abnormalities and Visual Outcomes in Pediatric Patients with NF1-associated Optic Pathway Gliomas: A Longitudinal Study. J Neuro-Ophthalmology 44(1): 5-9, 2024.
1b9 Plotkin SR, Allen J, Dhall G, Campian, JL, Clapp DW, Fisher MJ, Jain RK, Tonsgard J, Ullrich NJ, Thomas C, Edwards LJ, Korf B, Packer R, Karajannis MA, Blakeley JO: Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma. Neuro-Oncol 25(8): 1498-1506, Aug 2023.
2c